# Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma

> **NCT02507076** · NA · WITHDRAWN · sponsor: **Albert Einstein College of Medicine**

## Conditions studied

- Basal Cell Carcinoma of the Skin
- Eccrine Carcinoma of the Skin
- Recurrent Adult Soft Tissue Sarcoma
- Recurrent Melanoma
- Recurrent Skin Cancer
- Squamous Cell Carcinoma of the Skin
- Stage III Adult Soft Tissue Sarcoma
- Stage IIIB Melanoma
- Stage IIIC Melanoma
- Stage IV Adult Soft Tissue Sarcoma
- Stage IV Melanoma

## Interventions

- **DRUG:** isolated limb perfusion
- **DRUG:** melphalan
- **PROCEDURE:** quality-of-life assessment

## Key facts

- **NCT ID:** NCT02507076
- **Lead sponsor:** Albert Einstein College of Medicine
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2012-04
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** no enrollment
- **Last updated:** 2015-07-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02507076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02507076, "Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT02507076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*